Most people do not recognize cancer warning signs
the ONA take:
According to a new study published in the journal PLOS ONE, most people ignore cancer "alarm" symptoms. Researchers at University College London in London, United Kingdom, asked 1,724 participants aged 50 years and over whether they had experienced and of 17 cancer "alarm" symptoms.
Some symptoms included in the questionnaire were changes in mole appearance, difficulty swallowing, persistent change in bowel habits, unexplained bleeding, unexplained cough, unexplained lumps, and unexplained weight loss. Participants were not informed as to which symptoms are warning signs of cancer.
They were asked what they the thought to be the cause of any symptoms they experienced, as well as how serious they deemed the symptoms to be and if they visited the doctor as a result.
Of all respondents of the questionnaire, 53% reported experiencing at least one cancer warning symptom in the last 3 months and only 2% considered the warning symptoms to be cancer-related. Persistent cough and persistent change in bowel habits were the most common cancer warning signs experienced; unexplained weight loss and difficulty swallowing were the least.
Results showed that 59% of participants who experienced cancer signs visited a doctor. The findings suggest that many people who experience cancer signs do not realize the seriousness of their symptoms.
Most people ignore cancer "alarm" symptoms.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|